Company Profile
MorphoSys Stock Price, News & Analysis
- Ticker:
- MOR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Germany and listed in the U
Why the stock is moving
Current closing-price context is not available for MOR.
Company overview
Business overview
MorphoSys was a German antibody biotechnology company focused on oncology and immunology before its acquisition by Novartis. Its legacy value came from antibody discovery and partnered programs.
Geographic Base and Sector Classification
Headquartered in Germany and listed in the U.S. as an ADR before acquisition, MorphoSys was a global antibody-biotech name.
Business Model Characteristics
The business relied on partnered assets, royalties, and internal oncology development rather than a broad commercial base.
Position Within the Biotechnology Landscape
MorphoSys was a premium antibody platform name and now belongs to biotech M&A history.
Future catalysts
MorphoSys is now mostly a closeout story, so the catalysts are any remaining value-realization or legacy-asset update rather than a fresh pipeline milestone. The market is focused on what residual value is left.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does MorphoSys do?
MorphoSys was a German antibody biotechnology company focused on oncology and immunology before its acquisition by Novartis. Its legacy value came from antibody discovery and partnered programs.
On which exchange is MOR stock listed?
MorphoSys (MOR) is associated with NASDAQ, Germany and listed in the U, Biopharma.
What is MorphoSys?
MorphoSys is now mostly a closeout story, so the catalysts are any remaining value-realization or legacy-asset update rather than a fresh pipeline milestone.
Which conditions is MorphoSys targeting with MorphoSys?
MorphoSys is associated with oncology, immunology based on its company overview and current catalyst commentary.
How does MorphoSys describe recent progress with MorphoSys?
MorphoSys is now mostly a closeout story, so the catalysts are any remaining value-realization or legacy-asset update rather than a fresh pipeline milestone.
What is German?
MorphoSys was a German antibody biotechnology company focused on oncology and immunology before its acquisition by Novartis.
What should investors watch for with German?
MorphoSys is now mostly a closeout story, so the catalysts are any remaining value-realization or legacy-asset update rather than a fresh pipeline milestone. The market is focused on what residual value is left.
What is Novartis?
MorphoSys was a German antibody biotechnology company focused on oncology and immunology before its acquisition by Novartis.